Jan 9 (Reuters) - Valeant Pharmaceuticals International Inc (NYSE:VRX) VRX.TO said its affiliate will sell its Dendreon Pharmaceuticals business to China's Sanpower Group Co Ltd for $819.9 million in cash.
Valeant will use the proceeds to repay its term loan debt under its senior credit facility, the company said on Monday.